Literature DB >> 25941083

In the brain of mice, 3-iodothyronamine (T1AM) is converted into 3-iodothyroacetic acid (TA1) and it is included within the signaling network connecting thyroid hormone metabolites with histamine.

Annunziatina Laurino1, Gaetano De Siena2, Alessandro Saba3, Grazia Chiellini3, Elisa Landucci2, Riccardo Zucchi3, Laura Raimondi4.   

Abstract

3-iodothyronamine (T1AM) and its oxidative product, 3-iodotyhyroacetic acid (TTA1A), are known to stimulate learning and induce hyperalgesia in mice. We investigated whether i)TA1 may be generated in vivo from T1AM, ii) T1AM shares with TA1 the ability to activate the histaminergic system. Tandem mass spectrometry was used to measure TA1 and T1AM levels in i) the brain of mice following intracerebroventricular (i.c.v.) injection of T1AM (11μgkg(-1)), with or without pretreatment with clorgyline, (2.5mgkg(-1) i.p.), a monoamine oxidase inhibitor; ii) the medium of organotypic hippocampal slices exposed to T1AM (50nM). In addition, learning and pain threshold were evaluated by the light-dark box task and the hot plate test, respectively, in mice pre-treated subcutaneously with pyrilamine (10mgkg(-1)) or zolantidine (5mgkg(-1)), 20min before i.c.v. injection of T1AM (1.32 and 11μgkg(-1)). T1AM-induced hyperalgesia (1.32 and 11μgkg(-1)) was also evaluated in histidine decarboxylase (HDC(-/-)) mice. T1AM and TA1 brain levels increased in parallel in mice injected with T1AM with the TA1/T1AM averaging 1.7%. Clorgyline pre-treatment reduced the increase in both T1AM and TA1. TA1 was the main T1AM metabolite detected in the hippocampal preparations. Pretreatment with pyrilamine or zolantidine prevented the pro-learning effect of 1.32 and 4μgkg(-1) T1AM while hyperalgesia was conserved at the dose of 11μgkg(-1) T1AM. T1AM failed to induce hyperalgesia in HDC(-/-) mice at all the doses. In conclusion, TA1 generated from T1AM, but also T1AM, appears to act by modulating the histaminergic system.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3-iodothyroacetic acid; 3-iodothyronamine; 3-iodothyronamine (PubChem CID: 25844418); Histamine; Thyroid metabolites

Mesh:

Substances:

Year:  2015        PMID: 25941083     DOI: 10.1016/j.ejphar.2015.04.038

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Novel thyroid hormones.

Authors:  Riccardo Zucchi; Grazia Rutigliano; Federica Saponaro
Journal:  Endocrine       Date:  2019-07-20       Impact factor: 3.633

2.  N- and O-Acetylated 3-Iodothyronamines Have No Metabolic or Thermogenic Effects in Male Mice.

Authors:  Sogol Gachkar; Rebecca Oelkrug; Beate Herrmann; Thomas S Scanlan; Qian Sun; Heike Biebermann; Carolin S Hoefig; Lutz Schomburg; Jens Mittag
Journal:  Eur Thyroid J       Date:  2019-12-20

3.  Commentary: Torpor: The Rise and Fall of 3-Monoiodothyronamine from Brain to Gut-From Gut to Brain?

Authors:  Annunziatina Laurino; Laura Raimondi
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-22       Impact factor: 5.555

4.  New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection.

Authors:  Lorenza Bellusci; Annunziatina Laurino; Martina Sabatini; Simona Sestito; Paola Lenzi; Laura Raimondi; Simona Rapposelli; Francesca Biagioni; Francesco Fornai; Alessandra Salvetti; Leonardo Rossi; Riccardo Zucchi; Grazia Chiellini
Journal:  Front Pharmacol       Date:  2017-12-12       Impact factor: 5.810

Review 5.  Torpor: The Rise and Fall of 3-Monoiodothyronamine from Brain to Gut-From Gut to Brain?

Authors:  Hartmut H Glossmann; Oliver M D Lutz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-31       Impact factor: 5.555

6.  The Trace Amine-Associated Receptor 1 Agonist 3-Iodothyronamine Induces Biased Signaling at the Serotonin 1b Receptor.

Authors:  Julia Bräunig; Juliane Dinter; Carolin S Höfig; Sarah Paisdzior; Michal Szczepek; Patrick Scheerer; Mark Rosowski; Jens Mittag; Gunnar Kleinau; Heike Biebermann
Journal:  Front Pharmacol       Date:  2018-03-12       Impact factor: 5.810

Review 7.  Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases.

Authors:  Annunziatina Laurino; Elisa Landucci; Laura Raimondi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-06       Impact factor: 5.555

Review 8.  The Case for TAAR1 as a Modulator of Central Nervous System Function.

Authors:  Grazia Rutigliano; Alice Accorroni; Riccardo Zucchi
Journal:  Front Pharmacol       Date:  2018-01-10       Impact factor: 5.810

9.  Commentary: 3-Iodothyronamine Reduces Insulin Secretion In Vitro via a Mitochondrial Mechanism.

Authors:  Annunziatina Laurino; Laura Raimondi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-28       Impact factor: 5.555

10.  Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine.

Authors:  Xiaoqun Zhang; Ioannis Mantas; Alexandra Alvarsson; Takashi Yoshitake; Mohammadreza Shariatgorji; Marcela Pereira; Anna Nilsson; Jan Kehr; Per E Andrén; Mark J Millan; Karima Chergui; Per Svenningsson
Journal:  Front Pharmacol       Date:  2018-03-01       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.